Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

F. J. Giles, E. Abruzzese, G. Rosti, D. W. Kim, R. Bhatia, A. Bosly, S. Goldberg, G. L.S. Kam, M. Jagasia, W. Mendrek, T. Fischer, T. Facon, U. Dünzinger, D. Marin, M. C. Mueller, Y. Shou, N. J. Gallagher, R. A. Larson, F. X. Mahon, M. BaccaraniJ. Cortes, H. M. Kantarjian

Research output: Contribution to journal › Article › peer-review